Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 17/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3389528 | 0.99 | KDM1A (0.41) | KDM1AMAOBCCR5KMT2A | |
| SCHEMBL3394475 | 0.91 | CCR5 (0.43) | KDM1AMAOBCCR5KMT2A | |
| SCHEMBL3394478 | 0.91 | CCR5 (0.43) | KDM1AMAOBCCR5KMT2A | |
| SCHEMBL3391658 | 0.90 | CCR5 (0.49) | KDM1AMAOBCCR5 | |
| Hydrochloric Acid SCHEMBL3394816 | 0.90 | CCR5 (0.43) | KDM1AMAOBCCR5KMT2A | |
| SCHEMBL13043501 | 0.90 | CCR5 (0.41) | KDM1AMAOBCCR5KMT2A | |
| SCHEMBL3391654 | 0.90 | CCR5 (0.49) | KDM1AMAOBCCR5 | |
| Hydrochloric Acid SCHEMBL3394820 | 0.90 | CCR5 (0.43) | KDM1AMAOBCCR5KMT2A | |
| Hydrochloric Acid SCHEMBL3394489 | 0.89 | CCR5 (0.41) | KDM1AMAOBCCR5KMT2A | |
| Hydrochloric Acid SCHEMBL3394503 | 0.89 | CCR5 (0.48) | KDM1AMAOBCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | claimed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CXCR1, CXCR2, CXCR4 | KDM1A 4354/4885MAOB 3788/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.